ClinicalTrials.gg
CompletedNCT00838799Updated Jul 14, 2011

Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain

A Phase 2 interventional study of RGH-896 and RGH-896 in Diabetic Peripheral Neuropathic Pain, sponsored by Forest Laboratories. Completed at 54 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-07-14.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
458
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Pain by AbbVie — none open to participants now, none under way, none of them phase 3. Pain · AbbVie.

Enrollment
Largest of 17
458 · median 155
Started
2009
with 4 others
Phase 2
14 of 19
none open now
Registered
5th of 19
by date

Among the 19 studies in Pain by AbbVie, this one has the largest enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2009, is one of 14 in phase 2, and was the 5th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 19 studies in Pain by AbbVie is open now. The open studies under Pain, anywhere →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Pain by AbbVie as a file.
02

Study summary

This study is designed to evaluate the safety and efficacy of RGH-896 in patients with diabetic peripheral neuropathic pain.

03

Conditions studied

  • Diabetic Peripheral Neuropathic Pain

Keywords

  • diabetic
  • peripheral
  • neuropathic
  • pain
  • chronic
  • diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female outpatients 18 to 75 years of age
  • A diagnosis of painful diabetic neuropathy
  • Controlled blood glucose
  • Willingness to wash out all analgesic medications used for DPNP
  • Female patients either , surgically sterile, or practicing a medically acceptable method of
  • Female patients who are not pregnant

Exclusion criteria

Exclusion Criteria:

  • Acute infections or cardiac problems
  • Past use of pregabalin
  • History of severe psychiatric disorder
  • History of any amputation due to diabetes
  • History of seizure disorder
  • Active diabetic foot ulcers
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
458 participants (actual)

Study arms

  • Experimental
    1

    Drug: RGH-896

  • Experimental
    2

    Drug: RGH-896

  • Experimental
    3

    Drug: RGH-896

  • Active comparator
    4

    Drug: pregabalin

  • Placebo comparator
    5

    Drug: placebo

Interventions

  • 45 mg TID, capsules, 14 weeks.

  • 30 mg TID, capsules, 14 weeks.

  • 15 mg TID, capsules, 14 weeks.

  • 100 mg, TID, capsules, 14 weeks.

    Also known as: Lyrica

  • Drugplacebo

    TID, capsules, 14 weeks.

06

What researchers measure

Primary outcomes

  1. Change in mean daily pain rating

    Time frame: Baseline to Week 14

Secondary outcomes

  1. 50% reduction in pain

    Time frame: Baseline to Week 14

07

Study locations

54 sites
  • Forest Investigative Site
    Birmingham, Alabama 35242, United States
  • Forest Investigative Site
    Mesa, Arizona 85210, United States
  • Forest Investigative Site
    Tempe, Arizona 85282, United States
  • Forest Investigative Site
    Jonesboro, Arkansas 72401, United States
  • Forest Investigative Site
    Little Rock, Arkansas 72205, United States
  • Forest Investigative Site
    North Little Rock, Arkansas 72114, United States
  • Forest Investigative Site
    Anaheim, California 92801, United States
  • Forest Investigative Site
    Burbank, California 91505, United States
  • Forest Investigative Site
    Lakewood, California 90712, United States
  • Forest Investigative Site
    National City, California 91950, United States
  • Forest Investigative Site
    Riverside, California 92506, United States
  • Forest Investigative Site
    Sacramento, California 95821, United States
  • Forest Investigative Site
    San Diego, California 92117, United States
  • Forest Investigative Site
    Santa Monica, California 90404, United States
  • Forest Investigative Site
    Tustin, California 92780, United States
  • Forest Investigative Site
    Walnut Creek, California 94598, United States
  • Forest Investigative Site
    Westlake Village, California 91361, United States
  • Forest Investigative Site
    Boulder, Colorado 80304, United States
  • Forest Investigative Site
    New Britain, Connecticut 06050, United States
  • Forest Investigative Site
    Bradenton, Florida 34203, United States
  • Forest Investigative Site
    Brandon, Florida 33511, United States
  • Forest Investigative Site
    DeLand, Florida 32720, United States
  • Forest Investigative Site
    Hollywood, Florida 33023, United States
  • Forest Investigative Site
    Jacksonville, Florida 32216, United States
  • Forest Investigative Site
    Miami, Florida 33108, United States
  • Forest Investigative Site
    Orlando, Florida 32806, United States
  • Forest Investigative Site
    Pembroke Pines, Florida 33024, United States
  • Forest Investigative Site
    Tampa, Florida 33606, United States
  • Forest Investigative Site
    West Palm Beach, Florida 33401, United States
  • Forest Investigative Site
    Honolulu, Hawaii 96814, United States
  • Forest Investigative Site
    Boise, Idaho 83642, United States
  • Forest Investigative Site
    Wichita, Kansas 67203, United States
  • Forest Investigative Site
    Covington, Louisiana 70433, United States
  • Forest Investigative Site
    Owings Mills, Maryland 21117, United States
  • Forest Investigative Site
    St. Louis, Missouri 63141, United States
  • Forest Investigative Site
    West Caldwell, New Jersey 07006, United States
  • Forest Investigative Site
    Albuquerque, New Mexico 87108, United States
  • Forest Investigative Site
    New York, New York 10004, United States
  • Forest Investigative Site
    Charlotte, North Carolina 28211, United States
  • Forest Investigative Site
    Greenville, North Carolina 27834, United States
  • Forest Investigative Site
    Winston-Salem, North Carolina 27103, United States
  • Forest Investigative Site
    Cleveland, Ohio 44122, United States
  • Forest Investigative Site
    Kettering, Ohio 45429, United States
  • Forest Investigative Site
    Tulsa, Oklahoma 74104, United States
  • Forest Investigative Site
    Duncansville, Pennsylvania 16635, United States
  • Forest Investigative Site
    Philadelphia, Pennsylvania 19139, United States
  • Forest Investigative Site
    Columbia, South Carolina 29201, United States
  • Forest Investigative Site
    Memphis, Tennessee 38119, United States
  • Forest Investigative Site
    Dallas, Texas 75246, United States
  • Forest Investigative Site
    Lake Jackson, Texas 77566, United States
  • Forest Investigative Site
    San Antonio, Texas 78229, United States
  • Forest Investigative Site
    Salt Lake City, Utah 84106, United States
  • Forest Investigative Site
    Virginia Beach, Virginia 23454, United States
  • Forest Investigative Site
    Tacoma, Washington 98405, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009 and a primary completion of Apr 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2009
First posted
Feb 6, 2009
Start
Feb 2009
Primary completionActual
Apr 2010
Results delay requested
Jul 6, 2011
Last update
Jul 14, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00838799
Collaborators
Gedeon Richter Ltd.
First posted
Feb 6, 2009
Start date
Feb 2009
Primary completion
Apr 2010
Last update
Jul 14, 2011

Study contacts

Allyson Gage, PhD
study director · Forest Research Institute, a subsidiary of Forest Laboratories Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Radiprodil

Start the discussion